Integra Lifesciences Holdings CORP 8-K filings

Integra LifeSciences announced its second quarter 2026 financial results, showing modest revenue growth and improved earnings per share, while updating its full-year revenue guidance due to foreign exchange impacts.

Integra LifeSciences announced the appointment of Dr. Stuart Essig as President and CEO, effective May 1, 2026, succeeding Mojdeh Poul.

Integra LifeSciences reported strong first quarter 2026 results, exceeding expectations with increased revenues and improved profitability, while also raising full-year adjusted EPS guidance.

Integra LifeSciences has amended its $150 million accounts receivable securitization facility, extending the maturity date to April 10, 2029.

Integra LifeSciences reported a GAAP net loss for full-year 2025 driven by a significant goodwill impairment, alongside a decline in Q4 2025 revenues and adjusted earnings, while providing cautious 2026 guidance.

Integra LifeSciences Holdings Corporation has adopted a new Change in Control Severance Program for key executives, effective January 1, 2026.

Integra LifeSciences reported strong third-quarter adjusted earnings and revenue growth, exceeding expectations while making progress on supply chain and quality system improvements.

Integra LifeSciences reported a significant net loss in the second quarter of 2025 due to a $511 million goodwill impairment charge, while revenues slightly declined and adjusted earnings per share decreased, though revenues exceeded guidance and adjusted EPS met the top end of its range.

Integra LifeSciences Holdings Corporation has amended its credit agreement, adjusting its maximum consolidated total leverage ratio and implementing temporary restrictions on investments, indebtedness, and intellectual property transfers during a 'Covenant Relief Period' through late 2026.

Integra LifeSciences' stockholders approved an amendment to the company's equity incentive plan, increasing the number of shares available for awards by 2.2 million.

Integra LifeSciences' first quarter 2025 results show revenue growth but a decline in organic revenue and adjusted earnings per share, leading to a reduced full-year EPS guidance due to new tariffs.

Integra LifeSciences announced its Q4 and full-year 2024 financial results, showing revenue growth but a decline in full-year adjusted earnings, and provided its financial outlook for 2025.

Integra LifeSciences received an FDA warning letter regarding quality system issues at three facilities, but the company maintains its Q4 revenue guidance.

Integra LifeSciences has adopted a new change in control severance program for key executives, effective January 1, 2025, providing enhanced benefits in the event of a qualifying termination following a change in control.

Integra LifeSciences reported a decrease in revenue and earnings for the third quarter of 2024, impacted by supply chain issues and quality remediation efforts, while also announcing a new CEO.

Integra LifeSciences has announced the appointment of Mojdeh Poul as its new President and Chief Executive Officer, effective January 6, 2025, succeeding Jan De Witte.

Integra LifeSciences announced its second quarter 2024 financial results, showing revenue growth but reduced earnings per share and updated full-year guidance due to temporary shipping holds and compliance investments.

Integra LifeSciences has entered into an agreement to repurchase $50 million of its common stock through an accelerated share repurchase program.

Integra LifeSciences stockholders approved an amendment to their equity incentive plan, increasing the share pool by 1.9 million, and the company announced a $50 million share repurchase program.

Integra LifeSciences' first quarter results show a revenue decline of 3.1% on a reported basis, but the company has updated its full-year guidance to include the recent acquisition of Acclarent.

Integra LifeSciences has announced the retirement of CEO Jan De Witte by the end of 2024 and the appointment of Stuart Essig as Executive Chairman, effective immediately.

Integra LifeSciences reported a slight revenue decrease for Q4 2023 and a flat organic revenue for the full year, while providing 2024 revenue and adjusted earnings per share guidance.

Integra LifeSciences has amended its previous 8-K filing to include the committee assignment for newly appointed board member Jeffrey Alan Graves.